INM is a $4M market-cap shell whose value is purely a function of the Mentari merger closing. The FY2026 results confirm the company has no standalone path — cash is $2.2M with $1.8M in payables. Monitor for Form S-4 effectiveness and shareholder vote dates; deal failure would likely render INM equity worthless. The ~$490M pre-closing financing by Mentari provides a strong signal of institutional backing, but INM holders will be diluted into a small stub position in the combined entity.
Price Chart
Executive Summary
InMed Pharmaceuticals filed a Rule 425 communication reporting FY2026 annual results and providing a corporate update on its proposed merger with Mentari Therapeutics. The net loss widened to $12.6M from $8.2M, cash burned to $2.2M, and the company is a pre-revenue shell whose value is entirely tied to the pending reverse-merger into Mentari, which has raised ~$490M in pre-closing financing. The merger remains on track for Q4 2026 close, but InMed's standalone financials show a deteriorating cash position and no operating revenue, making this a binary event on deal completion.
Key Financial Metrics
Key Facts
- Net loss widened to $12.6M for FY2026 vs $8.2M in FY2025
- Cash and short-term investments fell to $2.2M from $10.7M year-over-year
- Merger with Mentari Therapeutics on track for Q4 2026 close; combined company to trade as MTRI
- Mentari raised ~$490M total pre-closing financing ($290M May + $200M July 2026)
- InMed's legacy pipeline (INM-901, INM-089, INM-755) to be monetized via CVR structure
- BayMedica subsidiary discontinued and wound down
- Form S-4 filed but not yet effective; shareholder votes pending
Financial Impact
Net loss of $12.6M on $0 revenue from continuing operations; cash burn of $8.6M from operations; cash runway effectively zero without merger proceeds
Risk Factors
- Merger fails to close — InMed has no revenue and insufficient cash to continue operations
- Shareholder or stockholder approval not obtained
- Form S-4 not declared effective by SEC
- Legacy InMed pipeline (CVRs) may never generate value
- Nasdaq continued-listing requirements may not be met
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001213900-26-098432 |
| Document: 0001213900-26-098432-index-headers.html | 0001213900-26-098432 |
| Document: 0001213900-26-098432-index.html | 0001213900-26-098432 |
| Document: 0001213900-26-098432.txt | 0001213900-26-098432 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 425 | $1.31 $1.39 | ▲ +6.11% | ▲ +6.61% | $1.33 (+1.53%) |
Jul 10, 2026 12w ago | 8-K | $1.57 $1.52 | ▲ +3.18% | ▲ +2.40% | $1.33 (+15.29%) |
Jul 2, 2026 13w ago | S-4 | $1.56 $1.66 | ▼ −6.41% | ▼ −5.48% | $1.33 (+14.74%) |
Jun 11, 2026 16w ago | Insider Cluster | $1.58 $1.49 | ▼ −5.70% | ▼ −6.13% | $1.33 (−15.82%) |
Jun 10, 2026 16w ago | 8-K | $1.51 $1.48 | ▼ −1.99% | ▼ −5.42% | $1.33 (−11.92%) |
May 19, 2026 19w ago | 425 | $1.60 $1.69 | ▲ +5.63% | ▲ +3.38% | $1.33 (−16.87%) |
May 19, 2026 19w ago | 8-K | $1.60 $1.69 | ▲ +5.63% | ▲ +3.38% | $1.33 (−16.87%) |
May 19, 2026 19w ago | 8-K | $1.60 $1.66 | ▼ −3.75% | ▼ −1.45% | $1.33 (+16.87%) |
Apr 27, 2026 22w ago | 8-K | $0.7010 $0.7480 | ▼ −6.70% | ▼ −5.01% | $1.33 (−89.73%) |
Apr 3, 2026 26w ago | 8-K | $0.6950 $0.7130 | ▲ +2.59% | ▼ −1.54% | $1.33 (+91.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access